Vivoryon Therapeutics N.V.

📍 Halle (Saale), Germany🗓 Founded 1997👥 21 employees💰 Last funded Oct 2025
Biotechnology Research🌐 vivoryon.com
Website LinkedIn
Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon’s most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease.
2
Total investors
0
Early stage
0
Mid stage
1
Late stage
1997
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Germany
1
France
1
Frequently asked questions
Who invested in Vivoryon Therapeutics N.V.?
Vivoryon Therapeutics N.V. has 2 investors on record on gritt.io and 1 late-stage investors.
When did Vivoryon Therapeutics N.V. last raise funding?
The most recent investment in Vivoryon Therapeutics N.V. recorded on gritt.io was in October 2025.
When was Vivoryon Therapeutics N.V. founded?
Vivoryon Therapeutics N.V. was founded in 1997.
What industry is Vivoryon Therapeutics N.V. in?
Vivoryon Therapeutics N.V. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Vivoryon Therapeutics N.V. based?
Vivoryon Therapeutics N.V. is headquartered in Halle (Saale), Germany.